Acro Biomedical Co., Ltd. (ACBM)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 | -15.86 Million USD | -106.27% |
| 2021 | -7.69 Million USD | -5797.13% |
| 2020 | -130.46 Thousand USD | 69.14% |
| 2019 | -301.73 Thousand USD | -182.0% |
| 2018 | 515.55 Thousand USD | 23033.72% |
| 2017 | -2248.00 USD | 94.82% |
| 2016 | - USD | 8.55% |
| 2015 | -47.49 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q1 | -4 Million USD | -1.77% |
| 2023 Q2 | -3.19 Million USD | 20.2% |
| 2022 FY | - USD | -106.27% |
| 2022 Q2 | -3.99 Million USD | -1.73% |
| 2022 Q3 | -4.01 Million USD | -0.36% |
| 2022 Q1 | -3.92 Million USD | -1.97% |
| 2022 Q4 | -3.93 Million USD | 1.92% |
| 2021 Q1 | -56.99 Thousand USD | 26.66% |
| 2021 Q2 | -793.32 Thousand USD | -1292.01% |
| 2021 Q3 | -2.99 Million USD | -276.98% |
| 2021 Q4 | -3.85 Million USD | -28.82% |
| 2021 FY | - USD | -5797.13% |
| 2020 Q3 | -71.54 Thousand USD | -13.97% |
| 2020 Q1 | 81.55 Thousand USD | 208.12% |
| 2020 FY | - USD | 69.14% |
| 2020 Q4 | -77.7 Thousand USD | -8.62% |
| 2020 Q2 | -62.77 Thousand USD | -176.97% |
| 2019 Q3 | -64.46 Thousand USD | 5.33% |
| 2019 Q1 | -214.76 Thousand USD | -127.9% |
| 2019 FY | - USD | -182.0% |
| 2019 Q4 | -75.43 Thousand USD | -17.02% |
| 2019 Q2 | -68.09 Thousand USD | 68.29% |
| 2018 Q4 | -94.23 Thousand USD | -158.5% |
| 2018 FY | - USD | 23033.72% |
| 2018 Q3 | 161.08 Thousand USD | -8.59% |
| 2018 Q2 | 176.22 Thousand USD | 79.8% |
| 2018 Q1 | 98.01 Thousand USD | 22.17% |
| 2017 FY | - USD | 94.82% |
| 2017 Q1 | -22.44 Thousand USD | -202.75% |
| 2017 Q2 | -11.88 Thousand USD | 47.03% |
| 2017 Q3 | 39.49 Thousand USD | 432.25% |
| 2017 Q4 | 80.22 Thousand USD | 103.13% |
| 2016 FY | - USD | 8.55% |
| 2016 Q4 | -7413.00 USD | -20.99% |
| 2016 Q3 | -6127.00 USD | 64.22% |
| 2016 Q2 | -17.12 Thousand USD | -169.69% |
| 2016 Q1 | -6350.00 USD | 54.07% |
| 2015 Q4 | -13.82 Thousand USD | -491.61% |
| 2015 Q2 | -18.00 USD | 37.93% |
| 2015 Q1 | -29.00 USD | 99.94% |
| 2015 FY | - USD | 0.0% |
| 2015 Q3 | -2337.00 USD | -12883.33% |
| 2014 Q4 | -50 Thousand USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 77.66% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -167.667% |
| SQZ Biotechnologies Company | -64.14 Million USD | 75.258% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 8.637% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 116.876% |
| Mesoblast Limited | -62.38 Million USD | 74.564% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -933.153% |
| Genus plc | 73.7 Million USD | 121.533% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -140.032% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -347.413% |
| Marizyme, Inc. | -34.28 Million USD | 53.708% |
| ContraFect Corporation | -64.99 Million USD | 75.585% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -80.914% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -250.62% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -1032.091% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -500.115% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -582.916% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -2963.384% |
| Accustem Sciences Inc. | -3.74 Million USD | -323.597% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 67.094% |
| EV Biologics, Inc. | -1.26 Million USD | -1152.414% |
| Q BioMed Inc. | -617.62 Thousand USD | -2469.465% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 544.282% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -2409.422% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -594.673% |
| Biomind Labs Inc. | -1.03 Million USD | -1433.976% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 260.674% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -121.605% |
| Skye Bioscience, Inc. | -13.54 Million USD | -17.141% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -966.936% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -63378.948% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -308.559% |
| IMV Inc. | -35.52 Million USD | 55.326% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -534.292% |
| GB Sciences, Inc. | -1.41 Million USD | -1017.678% |
| Alpha Cognition Inc. | -9.7 Million USD | -63.511% |
| HST Global, Inc. | -5303.00 USD | -299159.608% |
| CSL Limited | 4.78 Billion USD | 100.331% |
| Halberd Corporation | -74.27 Thousand USD | -21265.039% |
| Enzolytics Inc. | -2.12 Million USD | -647.857% |
| Resverlogix Corp. | -11.74 Million USD | -35.154% |
| Affymax, Inc. | -14.29 Million USD | -11.016% |
| SYBLEU INC | -141.57 Thousand USD | -11109.737% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -418.108% |
| argenx SE | -216.02 Million USD | 92.654% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 71.323% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 1404.005% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -958.755% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 4288.99% |
| AVAX Technologies, Inc. | -6.11 Million USD | -159.622% |
| Zenith Capital Corp. | -8.6 Million USD | -84.403% |
| Genscript Biotech Corporation | -248.71 Million USD | 93.619% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -90995.442% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -548.681% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -8915.648% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 59.962% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -448.684% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -1416.731% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 236116.315% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -806.843% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -726.157% |
| BioStem Technologies, Inc. | -7.55 Million USD | -110.094% |
| ONE Bio Corp. | 13.61 Million USD | 216.577% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -8663.55% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -671.499% |
| Agentix Corp. | -1.37 Million USD | -1056.892% |
| LadRx Corporation | 412.28 Thousand USD | 3949.234% |
| Cell Source, Inc. | -4.27 Million USD | -271.437% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -4221.577% |
| Regen BioPharma, Inc. | 1.46 Million USD | 1182.552% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -1593.767% |
| NovAccess Global Inc. | -1.03 Million USD | -1433.609% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 279.242% |
| Itoco Inc. | -1.86 Million USD | -749.105% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -4080.427% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -1322.019% |
| Kadimastem Ltd | -2.62 Million USD | -504.704% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -6535.893% |
| CytoDyn Inc. | -18.02 Million USD | 11.977% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -19980.903% |
| Mobile Lads Corp. | -2.24 Million USD | -608.104% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -129671.339% |
| Qrons Inc. | -40.08 Thousand USD | -39494.164% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -3167.543% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 3108.863% |
| Rebus Holdings, Inc. | -951 Thousand USD | -1568.742% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -1394.311% |
| International Stem Cell Corporation | 202 Thousand USD | 7956.305% |
| Bioxytran, Inc. | -3.82 Million USD | -315.422% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -30047.677% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -544.605% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 55.756% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -35166.082% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -479.611% |
| Neutra Corp. | -181.24 Thousand USD | -8655.862% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 21.277% |
| PureTech Health plc | -11.62 Million USD | -36.49% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 21.272% |
| IXICO plc | -707 Thousand USD | -2144.659% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -106.503% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 67.175% |
| CSL Limited | 4.73 Billion USD | 100.335% |
| Cellectis S.A. | -92.63 Million USD | 82.869% |